Protective effect of teprenone against indomethacin-induced small intestinal lesions in rats

Japanese Pharmacology and Therapeutics

Volumn 33, Issue 1, 2005, Pages 51-61

  Yokota, Aya ^a   Ohno, Ryoko ^a   Takahira, Yuka ^a   Tanaka, Akiko ^a   Takeuchi, Koji ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Indomethacin induced intestinal lesions; Mucus secretion; Nitric oxide; Prostaglandin content; Rat; Teprenone

Indexed keywords

16,16 DIMETHYLPROSTAGLANDIN E2 METHYL ESTER; DRUG VEHICLE; INDOMETACIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MYELOPEROXIDASE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE INHIBITOR; POLYSORBATE 80; TEPRENONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENTEROBACTERIACEAE; ENZYME ACTIVITY; ENZYME REGULATION; ILEUM DISEASE; INTESTINE INJURY; INTESTINE MOTILITY; INTESTINE MUCOSA; JAPAN; JEJUNUM DISEASE; MUCUS SECRETION; NONHUMAN; PROTEIN EXPRESSION; RAT;

EID: 21044457286     PISSN: 03863603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Hirakawa T, Rokutan K, Nishikawa T, Kishi K. Geranylgeranylacetone induces heat shock proteins in cultured guinea pig gastric mucosal cells and rat gastric mucosa. Gastroenterology 1996; 111: 345-57.
2. Tsukimi Y, Okabe S. Recent advances in gastrointestinal pathophysiology: Role of heat shock proteins in mucosal defense and ulcer healing. Biol Pharm Bull 2001; 24: 1-9.
3. Kunimoto S, Murofushi W, Yamatsu I, Hasegawa Y, Sasaki N, Kobayashi S, et al. Cholesteryl glucoside-induced protection against gastric ulcer. Cell Structure and Function 2003; 28: 179-86.
4. Ikeyama S, Kusumoto K, Miyake H, Rokutan K, Tashiro S. A non-toxic heat shock protein 70 inducer, geranylgeranylacetone, suppresses apoptosis of cultured rat hepatocytes caused by hydrogen peroxide and ethanol. J Hepatol 2001; 35: 53-61.
5. 2-receptor blocker or sucralfate, suppresses corpus Helicobacter pylori colonization and gastritis in humans: teprenone inhibition of H. pylori-induced interleukin-8 in MKN28 gastric epithelial cell lines. Helicobacter 2004; 9: 130-7.
6. Murakami M, Oketani K, Fujisaki H, Wakabayashi T, Ohgo T. Antiulcer effect of geranylgeranylacetone, a new acyclic polyisoprenoid on experimentally induced gastric and duodenal ulcers in rats. Arzneimittelforschung 1981; 31: 799-804.
7. Kobayashi T, Ohta Y, Yoshino J, Nakazawa S. Teprenone promotes the healing of acetic acid-induced chronic gastric ulcers in rats by inhibiting neutrophil infiltration and lipid peroxidation in ulcerated gastric tissues. Pharmacol Res 2001; 43: 23-30.
8. Fujimoto M, Yamanaka T, Bessho M, Igarashi T. Effects of geranylgeranylacetone on gastrointestinal secretion in rats. Eur J Pharmacol 1982; 77: 113-8.
9. Seno K, Joh T, Yokoyama Y, Itoh M. Role of mucus in gastric mucosal injury induced by local ischemia/reperfusion. J Lab Clin Med 1995; 126: 287-93.
10. Terano A, Hiraishi H, Ota S, Sugimoto T. Geranylgeranylacetone, a novel anti-ulcer drug, stimulates mucus synthesis and secretion in rat gastric cultured cells. Digestion 1986; 33: 206-10.
11. Dekigai H, Nakamura H, Bai J, Tanito M, Masutani H, Hirota K, et al. Geranylgeranylacetone promotes induction and secretion of thioredoxin in gastric mucosal cells and peripheral blood lymphocytes. Free Radic Res 2001; 35: 23-30.
12. Hirota K, Nakamura H, Masutani H, Yodoi J. Thioredoxin superfamily and thioredoxin-inducing agents. Ann N Y Acad Sci 2002; 957: 189-99. Review.
13. Hiraishi H, Terano A, Ota S, Mutoh H, Sugimoto T, Harada T, et al. Role for mucous glycoprotein in protecting cultured rat gastric mucosal cells against toxic oxygen metabolites. J Lab Clin Med 1993; 121: 570-8.
14. Nishida K, Ohta Y, Ishiguro I. Protective and preventive effects of teprenone on gastric mucosal lesions in rats. Eur J Pharmacol 1998 Jul 31; 354: 51-8.
15. Robert A. An intestinal disease produced experimentally by a prostaglandin deficiency. Gastroenterology 1975; 69: 1045-7.
16. Takeuchi K, Tanaka A, Ohno R, Yokota A. Role of COX inhibition in pathogenesis of NSAID-induced small intestinal damage. J Physiol Pharmacol 2003; 54: 165-82.
17. Takeuchi K, Miyazawa T, Tanaka A, Kato S, Kunikata T. Pathogenic importance of intestinal hypermotility in NSAID-induced small intestinal damage in rats. Digestion 2002; 66: 30-41.
18. Kunikata T, Miyazawa T, Kanatsu K, Kato S, Takeuchi K. Protective effect of thiaton, an antispasmodic drug, against indomethacin-induced intestinal damage in rats. Jpn J Pharmacol 2002; 88: 45-54.
19. Anthony A, Dhillon AP, Nygard G, Hudson M, Piasecki C, Strong P, et al. Early histological features of small intestinal injury induced by indomethacin. Aliment Pharmacol Ther 1993; 7: 29-39.
20. Tanaka A, Hase S, Miyazawa T, Takeuchi K. Up-regularion of cyclooxygenase-2 by inhibition of cyclooxygenase-1: a key to nonsteroidal anti-inflammatory drug-induced intestinal damage. J Pharmacol Exp Ther 2002; 300: 754-61.
21. Futaki N, Takahashi S, Yokoyama M, Arai I, Higuchi S, Otomo S. NS-398, a new antiinflammatory agent, selectively inhibits prostaglandin G/H synthase/ cyclo-oxygenase (COX-2) activity in vitro. Prostaglandins 1994; 47: 55-9.
22. Azumi Y, Ohara S, Ishihara K, Okabe H, Hotta K. Correlation of quantitave changes of gastric mucosal glycoproteins with aspirin-induced gastric damage in rats. Gut 1981; 21: 533-6.
23. Reuter BK, Davies NM, Wallace JL. Nonsteroidal antiinflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation. Gastroenterology 1997; 112: 109-17.
24. Krawisz JE, Sharon P, Stenson WF. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology 1984; 87: 1344-50.
25. Rokutan K, Teshima S, Kawai T, Kawahara T, Kusumoro K, Mizushima T, et al. Geranylgeranylacetone stimulates mucin synthesis in cultured guinea pig gastric pit cells by inducing a neuronal nitric oxide synthase. J Gastroenterol 2000; 35: 673-81.
26. 2-stimulated mucus secretion by rabbit gastric epithelial cells. Biochem Pharmacol 1999; 58: 1997-2002.
27. Miller TA. Protective effects of prostaglandins against gastric mucosal damage: current knowledge and proposed mechanisms. Am J Physiol 1983; 245: G601-G623.
28. Brown JF, Keates AC, Hanson PJ, Whittle BJ. Nitric oxide generators and cGMP stimulate mucus secretion by rat gastric mucosal cells. Am J Physiol 1993; 265: G418-G422.
29. Nishida K, Ohta Y, Ishiguro I. Teprenone, an anti-ulcer agent, increases gastric mucosal mucus level via nitric oxide in rats. Jpn J Pharmacol 1998; 78: 519-22.
30. Yoshikawa T, Naito J, Yoshida M, Kondo M. Mechanism in gastrointestinal mucosal injury induced by activated neutrophils. Microcirc Annu 1999; 15: 31-2.
31. Ohta Y, Kobayashi T, Inui K, Yoshino J, Nakazawa S. Protective effect of teprenone against acute gastric mucosal lesions induced by compound 48/80, a mast cell degranulator, in rats. J Pharmacol Sci 2003; 93: 337-46.
32. Fan XG, Chua A, Fan XJ, Keeling PW. Increased gastric production of interleukin-8 and tumour necrosis factor in patients with Helicobacter pylori infection. J Clin Pathol 1995; 48: 133-6.
33. Yoshimura N, Suzuki Y, Saito Y. Suppression of Helicobacter pylori-induced interleukin-8 production in gastric cancer cell lines by an anti-ulcer drug, geranylgeranylacetone. J Gastroenterol Hepatol 2002; 17: 1153-60.
34. Arakawa T, Yamada H, Nakamura A, Nebiki H, Satoh H, Fukuda T, et al. Gastric cytoprotection by tetraprenylacetone in human subjects. Digestion 1988; 39: 111-7.
35. Shirakabe H, Takemoto T, Kobayashi K, Ogoshi K, Kimura K, Nakamura K, et al. Clinical evaluation of teprenone, a mucosal protective agent, in the treatment of patients with gastric ulcers: a nationwide, multicenter clinical study. Clin Ther 1995; 17: 924-35.
36. Nagasawa Y, Tatsuta M, Iishi H, Ishiguro S. Prevention of gastric ulcer recurrence with tetraprenylacetone. Scand J Gastroenterol 1998; 33: 44-8.